{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T18:54:46Z","timestamp":1789412086683,"version":"build-2803163510"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,10,7]],"date-time":"2022-10-07T00:00:00Z","timestamp":1665100800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,10,7]],"date-time":"2022-10-07T00:00:00Z","timestamp":1665100800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Adipose-derived mesenchymal stem cells (ASCs) have gained attention as a new treatment for systemic sclerosis (SSc). Low-molecular-weight heparin (LMWH) enhances cell function and stimulates the production of hepatocyte growth factor (HGF) in a variety of cells. This study investigated the effects of LMWH on the functions of mouse ASCs (mASCs), and the therapeutic effects of mASCs activated with LMWH (hep-mASCs) in mouse models of SSc.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>The cellular functions of mASCs cultured with different concentrations of LMWH were determined. Mice were divided into four groups: bleomycin (BLM)-induced SSc (BLM-alone), BLM-induced SSc administered with mASCs (BLM-mASC), and BLM-induced SSc administered with mASCs activated with 10 or 100 \u03bcg\/mL LMWH (BLM-hep-mASC); there were 9 mice per group (<jats:italic>n<\/jats:italic> = 9). Skin inflammation and fibrosis were evaluated using histological and biochemical examinations and gene expression levels.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>In vitro assays showed that migration ability and HGF production were significantly higher in hep-mASCs than in mASCs alone. The mRNA expression levels of cell migration factors were significantly upregulated in hep-mASCs compared to those in mASCs alone. The hep-mASCs accumulated in the skin tissues more than mASCs alone. The thickness of skin and hydroxyproline content in BLM-hep-mASC groups were significantly decreased, and the skin mRNA expression levels of interleukin-2, \u03b1-smooth muscle actin, transforming growth factor \u03b21, collagen type 1 alpha 1, and tissue inhibitor of metalloproteinase 2 were significantly downregulated compared to those in the BLM-alone group.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>hep-mASCs showed higher anti-inflammatory and anti-fibrotic effects than mASCs alone and may be a promising candidate for SSc treatment.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13075-022-02915-6","type":"journal-article","created":{"date-parts":[[2022,10,7]],"date-time":"2022-10-07T05:02:30Z","timestamp":1665118950000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Therapeutic effects of adipose-derived mesenchymal stem\/stromal cells with enhanced migration ability and hepatocyte growth factor secretion by low-molecular-weight heparin treatment in bleomycin-induced mouse models of systemic sclerosis"],"prefix":"10.1186","volume":"24","author":[{"given":"Takayasu","family":"Suzuka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuya","family":"Kotani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shogo","family":"Matsuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takako","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tohru","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,10,7]]},"reference":[{"issue":"10103","key":"2915_CR1","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1016\/S0140-6736(17)30933-9","volume":"390","author":"CP Denton","year":"2017","unstructured":"Denton CP, Khanna D. Systemic sclerosis. Lancet. 2017;390(10103):1685\u201399.","journal-title":"Lancet."},{"issue":"10","key":"2915_CR2","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1038\/s41584-021-00683-2","volume":"17","author":"P Tsou","year":"2021","unstructured":"Tsou P, Varga J, O'Reilly S. Advances in epigenetics in systemic sclerosis: molecular mechanisms and therapeutic potential. Nat Rev Rheumatol. 2021;17(10):596\u2013607.","journal-title":"Nat Rev Rheumatol"},{"issue":"3 Suppl 33","key":"2915_CR3","first-page":"S87","volume":"22","author":"K Takehara","year":"2004","unstructured":"Takehara K. Treatment of early diffuse cutaneous systemic sclerosis patients in Japan by low-dose corticosteroids for skin involvement. Clin Exp Rheumatol. 2004;22(3 Suppl 33):S87\u20139.","journal-title":"Clin Exp Rheumatol"},{"issue":"3","key":"2915_CR4","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1517\/13543784.16.3.393","volume":"16","author":"SA Antoniu","year":"2007","unstructured":"Antoniu SA. Cyclophosphamide for scleroderma interstitial lung disease. Tashkin DP, Elashoff R, Clements PJ et al.: Cyclophosphamide versus placebo in scleroderma lung disease. N. Engl. J. Med. (2006) 354(25):2655-2666. Expert Opin Investig Drugs. 2007;16(3):393\u20135.","journal-title":"Expert Opin Investig Drugs"},{"issue":"7","key":"2915_CR5","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1002\/art.40114","volume":"69","author":"ER Volkmann","year":"2017","unstructured":"Volkmann ER, Tashkin DP, Li N, Roth MD, Khanna D, Hoffmann-Vold AM, et al. Mycophenolate mofetil versus placebo for systemic sclerosis-related interstitial lung disease: an analysis of scleroderma lung studies I and II. Arthritis Rheum. 2017;69(7):1451\u201360.","journal-title":"Arthritis Rheum"},{"issue":"12","key":"2915_CR6","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.2169\/internalmedicine.41.1118","volume":"41","author":"S Nagai","year":"2002","unstructured":"Nagai S, Hamada K, Shigematsu M, Taniyama M, Yamauchi S, Izumi T. Open-label compassionate use one year-treatment with pirfenidone to patients with chronic pulmonary fibrosis. Intern Med. 2002;41(12):1118\u201323.","journal-title":"Intern Med"},{"issue":"22","key":"2915_CR7","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1056\/NEJMoa1402584","volume":"370","author":"L Richeldi","year":"2014","unstructured":"Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2071\u201382.","journal-title":"N Engl J Med"},{"issue":"26","key":"2915_CR8","doi-asserted-by":"publisher","first-page":"2518","DOI":"10.1056\/NEJMoa1903076","volume":"380","author":"O Distler","year":"2019","unstructured":"Distler O, Highland KB, Gahlemann M, Azuma A, Fischer A, Mayes MD, et al. Nintedanib for systemic sclerosis-associated interstitial lung disease. N Engl J Med. 2019;380(26):2518\u201328.","journal-title":"N Engl J Med"},{"issue":"4","key":"2915_CR9","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.tice.2010.04.003","volume":"42","author":"MF Taha","year":"2010","unstructured":"Taha MF, Hedayati V. Isolation, identification and multipotential differentiation of mouse adipose tissue-derived stem cells. Tissue Cell. 2010;42(4):211\u20136.","journal-title":"Tissue Cell"},{"issue":"1","key":"2915_CR10","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1002\/ar.a.10039","volume":"272","author":"SS Tholpady","year":"2003","unstructured":"Tholpady SS, Katz AJ, Ogle RC. Mesenchymal stem cells from rat visceral fat exhibit multipotential differentiation in vitro. Anat Rec A Discov Mol Cell Evol Biol. 2003;272(1):398\u2013402.","journal-title":"Anat Rec A Discov Mol Cell Evol Biol"},{"key":"2915_CR11","doi-asserted-by":"publisher","first-page":"e54","DOI":"10.1038\/emm.2013.94","volume":"45","author":"MB Murphy","year":"2013","unstructured":"Murphy MB, Moncivais K, Caplan AI. Mesenchymal stem cells: environmentally responsive therapeutics for regenerative medicine. Exp Mol Med. 2013;45:e54.","journal-title":"Exp Mol Med"},{"issue":"3","key":"2915_CR12","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1513\/pats.201201-010AW","volume":"9","author":"K McNulty","year":"2012","unstructured":"McNulty K, Janes SM. Stem cells and pulmonary fibrosis: cause or cure? Proc Am Thorac Soc. 2012;9(3):164\u201371.","journal-title":"Proc Am Thorac Soc"},{"issue":"5","key":"2915_CR13","doi-asserted-by":"publisher","first-page":"S45","DOI":"10.1513\/AnnalsATS.201304-090AW","volume":"10","author":"DJ Weiss","year":"2013","unstructured":"Weiss DJ. Stem cells, cell therapies, and bioengineering in lung biology and diseases. Comprehensive review of the recent literature 2010-2012. Ann Am Thorac Soc. 2013;10(5):S45\u201397.","journal-title":"Ann Am Thorac Soc"},{"issue":"10","key":"2915_CR14","doi-asserted-by":"publisher","first-page":"e47559","DOI":"10.1371\/journal.pone.0047559","volume":"7","author":"MM Lalu","year":"2012","unstructured":"Lalu MM, McIntyre L, Pugliese C, Fergusson D, Winston BW, Marshall JC, et al. Safety of cell therapy with mesenchymal stromal cells (SafeCell): a systematic review and meta-analysis of clinical trials. PLoS One. 2012;7(10):e47559.","journal-title":"PLoS One"},{"issue":"10","key":"2915_CR15","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1161\/01.CIR.0000121425.42966.F1","volume":"109","author":"J Rehman","year":"2004","unstructured":"Rehman J, Traktuev D, Li J, Merfeld-Clauss S, Temm-Grove CJ, Bovenkerk JE, et al. Secretion of angiogenic and antiapoptotic factors by human adipose stromal cells. Circulation. 2004;109(10):1292\u20138.","journal-title":"Circulation."},{"issue":"7","key":"2915_CR16","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1016\/j.yexcr.2007.12.022","volume":"314","author":"D Noel","year":"2008","unstructured":"Noel D, Caton D, Roche S, Bony C, Lehmann S, Casteilla L, et al. Cell specific differences between human adipose-derived and mesenchymal-stromal cells despite similar differentiation potentials. Exp Cell Res. 2008;314(7):1575\u201384.","journal-title":"Exp Cell Res"},{"issue":"1-2","key":"2915_CR17","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.imlet.2009.07.010","volume":"126","author":"E Ivanova-Todorova","year":"2009","unstructured":"Ivanova-Todorova E, Bochev I, Mourdjeva M, Dimitrov R, Bukarev D, Kyurkchiev S, et al. Adipose tissue-derived mesenchymal stem cells are more potent suppressors of dendritic cells differentiation compared to bone marrow-derived mesenchymal stem cells. Immunol Lett. 2009;126(1-2):37\u201342.","journal-title":"Immunol Lett"},{"issue":"2","key":"2915_CR18","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.jdermsci.2007.08.004","volume":"49","author":"WS Kim","year":"2008","unstructured":"Kim WS, Park BS, Kim HK, Park JS, Kim KJ, Choi JS, et al. Evidence supporting antioxidant action of adipose-derived stem cells: protection of human dermal fibroblasts from oxidative stress. J Dermatol Sci. 2008;49(2):133\u201342.","journal-title":"J Dermatol Sci"},{"issue":"7","key":"2915_CR19","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1517\/14712590903039684","volume":"9","author":"WS Kim","year":"2009","unstructured":"Kim WS, Park BS, Sung JH. The wound-healing and antioxidant effects of adipose-derived stem cells. Expert Opin Biol Ther. 2009;9(7):879\u201387.","journal-title":"Expert Opin Biol Ther"},{"issue":"117","key":"2915_CR20","first-page":"606","volume":"27","author":"JT Sinski","year":"1966","unstructured":"Sinski JT, Pannier WL. Re-test reaction in tuberculous monkeys. Am J Vet Res. 1966;27(117):606\u20138.","journal-title":"Am J Vet Res"},{"key":"2915_CR21","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.carres.2014.06.023","volume":"403","author":"B Casu","year":"2015","unstructured":"Casu B, Naggi A, Torri G. Re-visiting the structure of heparin. Carbohydr Res. 2015;403:60\u20138.","journal-title":"Carbohydr Res"},{"issue":"2","key":"2915_CR22","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1056\/NEJM199307083290212","volume":"329","author":"DA Lane","year":"1993","unstructured":"Lane DA, Adams L. Non-anticoagulant uses of heparin. N Engl J Med. 1993;329(2):129\u201330.","journal-title":"N Engl J Med"},{"issue":"28","key":"2915_CR23","doi-asserted-by":"publisher","first-page":"16871","DOI":"10.1074\/jbc.270.28.16871","volume":"270","author":"TF Zioncheck","year":"1995","unstructured":"Zioncheck TF, Richardson L, Liu J, Chang L, King KL, Bennett GL, et al. Sulfated oligosaccharides promote hepatocyte growth factor association and govern its mitogenic activity. J Biol Chem. 1995;270(28):16871\u20138.","journal-title":"J Biol Chem"},{"issue":"6","key":"2915_CR24","doi-asserted-by":"publisher","first-page":"3594","DOI":"10.1074\/jbc.M705621200","volume":"283","author":"N Sasaki","year":"2008","unstructured":"Sasaki N, Okishio K, Ui-Tei K, Saigo K, Kinoshita-Toyoda A, Toyoda H, et al. Heparan sulfate regulates self-renewal and pluripotency of embryonic stem cells. J Biol Chem. 2008;283(6):3594\u2013606.","journal-title":"J Biol Chem"},{"issue":"36","key":"2915_CR25","doi-asserted-by":"publisher","first-page":"13409","DOI":"10.1073\/pnas.0806136105","volume":"105","author":"MK Furue","year":"2008","unstructured":"Furue MK, Na J, Jackson JP, Okamoto T, Jones M, Baker D, et al. Heparin promotes the growth of human embryonic stem cells in a defined serum-free medium. Proc Natl Acad Sci U S A. 2008;105(36):13409\u201314.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"34","key":"2915_CR26","doi-asserted-by":"publisher","first-page":"26233","DOI":"10.1074\/jbc.M110.122069","volume":"285","author":"L Ling","year":"2010","unstructured":"Ling L, Dombrowski C, Foong KM, Haupt LM, Stein GS, Nurcombe V, et al. Synergism between Wnt3a and heparin enhances osteogenesis via a phosphoinositide 3-kinase\/Akt\/RUNX2 pathway. J Biol Chem. 2010;285(34):26233\u201344.","journal-title":"J Biol Chem"},{"issue":"6","key":"2915_CR27","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1093\/oxfordjournals.jbchem.a124262","volume":"114","author":"K Matsumoto","year":"1993","unstructured":"Matsumoto K, Tajima H, Okazaki H, Nakamura T. Heparin as an inducer of hepatocyte growth factor. J Biochem. 1993;114(6):820\u20136.","journal-title":"J Biochem"},{"issue":"1","key":"2915_CR28","doi-asserted-by":"publisher","first-page":"19019","DOI":"10.1038\/s41598-020-76034-0","volume":"10","author":"T Saito","year":"2020","unstructured":"Saito T, Kotani T, Suzuki K. Antifibrotic therapy by sustained release of low molecular weight heparin from poly(lactic-co-glycolic acid) microparticles on bleomycin-induced pulmonary fibrosis in mice. Sci Rep. 2020;10(1):19019.","journal-title":"Sci Rep"},{"issue":"9","key":"2915_CR29","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1056\/NEJM200103013440901","volume":"344","author":"AG Turpie","year":"2001","unstructured":"Turpie AG, Gallus AS, Hoek JA, Pentasaccharide I. A synthetic pentasaccharide for the prevention of deep-vein thrombosis after total hip replacement. N Engl J Med. 2001;344(9):619\u201325.","journal-title":"N Engl J Med"},{"issue":"5","key":"2915_CR30","first-page":"807","volume":"99","author":"E Gray","year":"2008","unstructured":"Gray E, Mulloy B, Barrowcliffe TW. Heparin and low-molecular-weight heparin. Thromb Haemost. 2008;99(5):807\u201318.","journal-title":"Thromb Haemost"},{"issue":"5","key":"2915_CR31","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1093\/jb\/mvm067","volume":"141","author":"R Sakiyama","year":"2007","unstructured":"Sakiyama R, Fukuta K, Matsumoto K, Furukawa M, Takahashi Y, Nakamura T. Stimulation of hepatocyte growth factor production by heparin-derived oligosaccharides. J Biochem. 2007;141(5):653\u201360.","journal-title":"J Biochem"},{"issue":"1","key":"2915_CR32","doi-asserted-by":"publisher","first-page":"14608","DOI":"10.1038\/s41598-017-15022-3","volume":"7","author":"T Kotani","year":"2017","unstructured":"Kotani T, Masutani R, Suzuka T, Oda K, Makino S, Ii M. Anti-inflammatory and anti-fibrotic effects of intravenous adipose-derived stem cell transplantation in a mouse model of bleomycin-induced interstitial pneumonia. Sci Rep. 2017;7(1):14608.","journal-title":"Sci Rep"},{"issue":"8","key":"2915_CR33","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/s00403-005-0635-z","volume":"297","author":"T Yamamoto","year":"2006","unstructured":"Yamamoto T. The bleomycin-induced scleroderma model: what have we learned for scleroderma pathogenesis? Arch Dermatol Res. 2006;297(8):333\u201344.","journal-title":"Arch Dermatol Res"},{"issue":"2","key":"2915_CR34","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1111\/1756-185X.13764","volume":"23","author":"A Okamura","year":"2020","unstructured":"Okamura A, Matsushita T, Komuro A, Kobayashi T, Maeda S, Hamaguchi Y, et al. Adipose-derived stromal\/stem cells successfully attenuate the fibrosis of scleroderma mouse models. Int J Rheum Dis. 2020;23(2):216\u201325.","journal-title":"Int J Rheum Dis"},{"key":"2915_CR35","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.jaut.2016.03.013","volume":"70","author":"AT Maria","year":"2016","unstructured":"Maria AT, Toupet K, Maumus M, Fonteneau G, Le Quellec A, Jorgensen C, et al. Human adipose mesenchymal stem cells as potent anti-fibrosis therapy for systemic sclerosis. J Autoimmun. 2016;70:31\u20139.","journal-title":"J Autoimmun"},{"issue":"5","key":"2915_CR36","doi-asserted-by":"publisher","first-page":"779","DOI":"10.3727\/096368912X639017","volume":"22","author":"N Scuderi","year":"2013","unstructured":"Scuderi N, Ceccarelli S, Onesti MG, Fioramonti P, Guidi C, Romano F, et al. Human adipose-derived stromal cells for cell-based therapies in the treatment of systemic sclerosis. Cell Transplant. 2013;22(5):779\u201395.","journal-title":"Cell Transplant"},{"issue":"5","key":"2915_CR37","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.3349\/ymj.2013.54.5.1293","volume":"54","author":"JW Jung","year":"2013","unstructured":"Jung JW, Kwon M, Choi JC, Shin JW, Park IW, Choi BW, et al. Familial occurrence of pulmonary embolism after intravenous, adipose tissue-derived stem cell therapy. Yonsei Med J. 2013;54(5):1293\u20136.","journal-title":"Yonsei Med J"},{"issue":"1","key":"2915_CR38","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s13287-016-0444-7","volume":"8","author":"M Griffin","year":"2017","unstructured":"Griffin M, Ryan CM, Pathan O, Abraham D, Denton CP, Butler PE. Characteristics of human adipose derived stem cells in scleroderma in comparison to sex and age matched normal controls: implications for regenerative medicine. Stem Cell Res Ther. 2017;8(1):23.","journal-title":"Stem Cell Res Ther"},{"issue":"10","key":"2915_CR39","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1007\/s00296-019-04401-w","volume":"39","author":"C Corallo","year":"2019","unstructured":"Corallo C, Fioravanti A, Tenti S, Pecetti G, Nuti R, Giordano N. Sarcopenia in systemic sclerosis: the impact of nutritional, clinical, and laboratory features. Rheumatol Int. 2019;39(10):1767\u201375.","journal-title":"Rheumatol Int"},{"issue":"4","key":"2915_CR40","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.3390\/ijms21041306","volume":"21","author":"L Mazini","year":"2020","unstructured":"Mazini L, Rochette L, Admou B, Amal S, Malka G. Hopes and limits of adipose-derived stem cells (ADSCs) and mesenchymal stem cells (MSCs) in wound healing. Int J Mol Sci. 2020;21(4):1306.","journal-title":"Int J Mol Sci"},{"issue":"4","key":"2915_CR41","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.autrev.2014.11.013","volume":"14","author":"N Molnarfi","year":"2015","unstructured":"Molnarfi N, Benkhoucha M, Funakoshi H, Nakamura T, Lalive PH. Hepatocyte growth factor: a regulator of inflammation and autoimmunity. Autoimmun Rev. 2015;14(4):293\u2013303.","journal-title":"Autoimmun Rev"},{"issue":"11","key":"2915_CR42","doi-asserted-by":"publisher","first-page":"e15384","DOI":"10.1371\/journal.pone.0015384","volume":"5","author":"GM Coudriet","year":"2010","unstructured":"Coudriet GM, He J, Trucco M, Mars WM, Piganelli JD. Hepatocyte growth factor modulates interleukin-6 production in bone marrow derived macrophages: implications for inflammatory mediated diseases. PLoS One. 2010;5(11):e15384.","journal-title":"PLoS One"},{"issue":"3","key":"2915_CR43","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1093\/oxfordjournals.jbchem.a124958","volume":"118","author":"Y Matsuda","year":"1995","unstructured":"Matsuda Y, Matsumoto K, Ichida T, Nakamura T. Hepatocyte growth factor suppresses the onset of liver cirrhosis and abrogates lethal hepatic dysfunction in rats. J Biochem. 1995;118(3):643\u20139.","journal-title":"J Biochem"},{"issue":"4 Suppl 91","key":"2915_CR44","first-page":"S197","volume":"33","author":"HL Cao","year":"2015","unstructured":"Cao HL, Dou TT, Yang JQ, Jing J, Zheng M, Man XY. The antifibrotic role of hepatocyte growth factor in dermal fibroblasts of systemic sclerosis. Clin Exp Rheumatol. 2015;33(4 Suppl 91):S197\u20138.","journal-title":"Clin Exp Rheumatol"},{"issue":"2","key":"2915_CR45","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1038\/sj.gt.3302165","volume":"11","author":"MH Wu","year":"2004","unstructured":"Wu MH, Yokozeki H, Takagawa S, Yamamoto T, Satoh T, Kaneda Y, et al. Hepatocyte growth factor both prevents and ameliorates the symptoms of dermal sclerosis in a mouse model of scleroderma. Gene Ther. 2004;11(2):170\u201380.","journal-title":"Gene Ther"},{"issue":"1","key":"2915_CR46","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/gt.2016.64","volume":"24","author":"S Chen","year":"2017","unstructured":"Chen S, Chen X, Wu X, Wei S, Han W, Lin J, et al. Hepatocyte growth factor-modified mesenchymal stem cells improve ischemia\/reperfusion-induced acute lung injury in rats. Gene Ther. 2017;24(1):3\u201311.","journal-title":"Gene Ther"},{"issue":"3","key":"2915_CR47","first-page":"1487","volume":"41","author":"M Tang","year":"2018","unstructured":"Tang M, Bian W, Cheng L, Zhang L, Jin R, Wang W, et al. Ginsenoside Rg3 inhibits keloid fibroblast proliferation, angiogenesis and collagen synthesis in vitro via the TGF-\u03b2\/Smad and ERK signaling pathways. Int J Mol Med. 2018;41(3):1487\u201399.","journal-title":"Int J Mol Med"},{"issue":"14","key":"2915_CR48","doi-asserted-by":"publisher","first-page":"9952","DOI":"10.1074\/jbc.M113.545822","volume":"289","author":"S O'Reilly","year":"2014","unstructured":"O'Reilly S, Ciechomska M, Cant R, van Laar MJ. Interleukin-6 (IL-6) trans signaling drives a STAT3-dependent pathway that leads to hyperactive transforming growth factor-\u03b2 (TGF-\u03b2) signaling promoting SMAD3 activation and fibrosis via Gremlin protein. J Biol Chem. 2014;289(14):9952\u201360.","journal-title":"J Biol Chem"},{"key":"2915_CR49","doi-asserted-by":"publisher","first-page":"681061","DOI":"10.3389\/fcell.2021.681061","volume":"9","author":"L Duffy","year":"2021","unstructured":"Duffy L, Henderson J, Brown M, Pryzborski S, Fullard N, Summa L, et al. Bone morphogenetic protein antagonist gremlin-1 increases myofibroblast transition in dermal fibroblasts: implications for systemic sclerosis. Front Cell Dev Biol. 2021;9:681061.","journal-title":"Front Cell Dev Biol"},{"issue":"11","key":"2915_CR50","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.3389\/fimmu.2020.01142","volume":"26","author":"M Zhang","year":"2020","unstructured":"Zhang M, Zhang S. T Cells in Fibrosis and Fibrotic Diseases. Front Immunol. 2020;26(11):1142.","journal-title":"Front Immunol"}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-022-02915-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13075-022-02915-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-022-02915-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,7]],"date-time":"2022-10-07T06:22:00Z","timestamp":1665123720000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-022-02915-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,7]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["2915"],"URL":"https:\/\/doi.org\/10.1186\/s13075-022-02915-6","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,7]]},"assertion":[{"value":"2 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Institutional Animal Care and Use Committee of Osaka Medical and Pharmaceutical University approved all of the following research protocols (approval ID: 21050-A), including the surgical procedures and animal care, and all methods were performed in accordance with the relevant guidelines and regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"228"}}